Achillion Pharmaceuticals (ACHN) Shares Rise On Positive Results Of Six-Week Combo Hepatitis C Treatment — ACH-3102

February 10, 2015 1:20 AM

13 0

The stock rose on the upbeat results of the phase II study the biopharmaceutical conducted for a hepatitis C drug cocktail; AbbVie and Gilead face a potential contraction in market share

Before the opening bell today, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), announced positive interim results from the phase II study of ACH-3102 in combination with Gilead Sciences, Inc.’s (NASDAQ:GILD) Sovaldi, establishing the cocktail drug’s ability to cure Hepatitis C in six weeks. This is t...

Read more

To category page